Literature DB >> 15876907

Activity of citalopram on adenosine and serotonin circulating levels in depressed patients.

Patrizia Blardi1, Arianna de Lalla, Renato Urso, Alberto Auteri, Alice Dell'Erba, Letizia Bossini, Paolo Castrogiovanni.   

Abstract

Citalopram is a selective serotonin reuptake inhibitor used in the treatment of depression. Recent investigations have shown that it reduces in rat brain the release of excitatory amino neurotransmitters acid glutamate and aspartate by the involvement of the inhibitory neuromodulator adenosine. In this study, we described citalopram and serotonin levels in plasma and platelets, as well as plasma adenosine levels, in depressive patients during acute and chronic administration of citalopram. Twelve patients affected by Major Depression (DSM-IV) received a single oral dose of citalopram in the morning, 5 mg in the first 5 days, 10 mg from the 6th to the 10th day, and 20 mg from the 11th to the 40th day. Blood samples for citalopram, serotonin, and adenosine were collected at Time 0 and 4, 12 and 24 hours after drug administration on the first day of citalopram 5 mg, and on the first and the last day of citalopram 20 mg. Citalopram, serotonin, and adenosine concentrations in plasma increased after citalopram administration, and the highest levels were observed on the last day of treatment. Citalopram was detectable in platelets with concentrations showing a time variation similar to plasma values. Serotonin levels in platelets decreased after drug administration, reaching the lowest values on the last day of treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876907     DOI: 10.1097/01.jcp.0000161500.58266.90

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  8 in total

1.  Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.

Authors:  V Bhagya; B N Srikumar; T R Raju; B S Shankaranarayana Rao
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

Review 2.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

3.  Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A₁ and A2A receptor activation.

Authors:  Mauricio P Cunha; Francis L Pazini; Julia M Rosa; Ana B Ramos-Hryb; Ágatha Oliveira; Manuella P Kaster; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2015-02-22       Impact factor: 3.765

4.  Antidepressants and anti-inflammatory drugs differentially reduce the release of NGF and BDNF from rat platelets.

Authors:  T Hochstrasser; D Ehrlich; B Sperner-Unterweger; C Humpel
Journal:  Pharmacopsychiatry       Date:  2012-06-14       Impact factor: 5.788

5.  Plasma serotonin levels are associated with antidepressant response to SSRIs.

Authors:  Amanda Holck; Owen M Wolkowitz; Sindy H Mellon; Victor I Reus; J Craig Nelson; Åsa Westrin; Daniel Lindqvist
Journal:  J Affect Disord       Date:  2019-02-26       Impact factor: 4.839

6.  Antidepressant effect of taurine in chronic unpredictable mild stress-induced depressive rats.

Authors:  Gao-Feng Wu; Shuang Ren; Ri-Yi Tang; Chang Xu; Jia-Qi Zhou; Shu-Mei Lin; Ying Feng; Qun-Hui Yang; Jian-Min Hu; Jian-Cheng Yang
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

7.  Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease.

Authors:  Luke Whiley; Katie E Chappell; Ellie D'Hondt; Matthew R Lewis; Beatriz Jiménez; Stuart G Snowden; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Jonathan R Swann; Abdul Hye; Simon Lovestone; Cristina Legido-Quigley; Elaine Holmes
Journal:  Alzheimers Res Ther       Date:  2021-01-09       Impact factor: 6.982

8.  TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.

Authors:  M Gupta; D Neavin; D Liu; J Biernacka; D Hall-Flavin; W V Bobo; M A Frye; M Skime; G D Jenkins; A Batzler; K Kalari; W Matson; S S Bhasin; H Zhu; T Mushiroda; Y Nakamura; M Kubo; L Wang; R Kaddurah-Daouk; R M Weinshilboum
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.